Subcutaneous Versus Intravenous Nivolumab Formulations: Important Considerations for Patient Care
September 23, 2025
In December 2024, the FDA approved a subcutaneous formulation of the immune checkpoint inhibitor nivolumab across adult, solid tumor nivolumab…